These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 36169807)
1. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial. Verschraegen C; Andric Z; Moiseenko F; Makharadze T; Shevnya S; Oleksiienko A; Yañez Ruiz E; Kim S; Ahn K; Park T; Park S; Ju H; Ohe Y BioDrugs; 2022 Nov; 36(6):749-760. PubMed ID: 36169807 [TBL] [Abstract][Full Text] [Related]
2. PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin Reinmuth N; Bryl M; Bondarenko I; Syrigos K; Vladimirov V; Zereu M; Bair AH; Hilton F; Liau K; Kasahara K BioDrugs; 2019 Oct; 33(5):555-570. PubMed ID: 31338773 [TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA). Trukhin D; Poddubskaya E; Andric Z; Makharadze T; Bellala RS; Charoentum C; Yañez Ruiz EP; Fulop A; Hyder Ali IA; Syrigos K; Katgi N; Lopez Chuken YA; Rumyana I; Reyes-Igama J; Costamilan RC; Del Campo García A; Florez A; Paravisini A; Millan S; BioDrugs; 2021 Jul; 35(4):429-444. PubMed ID: 33914256 [TBL] [Abstract][Full Text] [Related]
4. Bevacizumab biosimilar candidate TAB008 compared to Avastin Lu S; Qin S; Zhou Z; Chen J; Gu K; Sun P; Pan Y; Yu G; Ma K; Shi J; Sun Y; Yang L; Chen P; Liu A; He J J Cancer Res Clin Oncol; 2023 Aug; 149(9):5907-5914. PubMed ID: 36595042 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC). Syrigos K; Abert I; Andric Z; Bondarenko IN; Dvorkin M; Galic K; Galiulin R; Kuchava V; Sriuranpong V; Trukhin D; Zhavrid E; Fu D; Kassalow LM; Jones S; Bashir Z; BioDrugs; 2021 Jul; 35(4):417-428. PubMed ID: 34264503 [TBL] [Abstract][Full Text] [Related]
6. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab. Stroyakovskiy DL; Fadeeva NV; Matrosova MP; Shelepen KG; Adamchuk GA; Roy B; Nagarkar R; Kalloli M; Zhuravleva D; Voevodin GD; Shustova MS; Kryukov F BMC Cancer; 2022 Feb; 22(1):129. PubMed ID: 35105329 [TBL] [Abstract][Full Text] [Related]
7. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. Reck M; Luft A; Bondarenko I; Shevnia S; Trukhin D; Kovalenko NV; Vacharadze K; Andrea F; Hontsa A; Choi J; Shin D Lung Cancer; 2020 Aug; 146():12-18. PubMed ID: 32502923 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study. Chen L; Rangel JDG; Cil T; Li X; Cicin I; Shen Y; Liu Z; Ozyilkan O; Igor B; Chen J; Oleksandr K; Chen Z; Zhang H; Fu Z; Dong Q; Song S; Yu JC; Zhang L Cancer Med; 2023 Nov; 12(22):20847-20863. PubMed ID: 37935428 [TBL] [Abstract][Full Text] [Related]
9. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males. Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957 [TBL] [Abstract][Full Text] [Related]
10. Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial. Shi Y; Lei K; Jia Y; Ni B; He Z; Bi M; Wang X; Shi J; Zhou M; Sun Q; Wang G; Chen D; Shu Y; Liu L; Guo Z; Liu Y; Yang J; Wang K; Xiao K; Wu L; Yi T; Sun D; Kang M; Ma T; Mao Y; Shi J; Tang T; Wang Y; Xing P; Lv D; Liao W; Luo Z; Wang B; Wu X; Zhu X; Han S; Guo Q; Liu R; Lu Z; Zhang J; Fang J; Hu C; Ji Y; Liu G; Lu H; Wu D; Zhang J; Zhu S; Liu Z; Qiu W; Ye F; Yu Y; Zhao Y; Zheng Q; Chen J; Pan Z; Zhang Y; Lian W; Jiang B; Qiu B; Zhang G; Zhang H; Chen Y; Chen Y; Duan H; Li M; Liu S; Ma L; Pan H; Yuan X; Yuan X; Zheng Y; Gao E; Zhao L; Wang S; Wu C Cancer Commun (Lond); 2021 Sep; 41(9):889-903. PubMed ID: 34184418 [TBL] [Abstract][Full Text] [Related]
11. Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer. Socinski MA; Waller CF; Idris T; Bondarenko I; Luft A; Beckmann K; Vishweswaramurthy A; Loganathan S; Donnelly C; Hummel MA; Shapiro R; Woods M; Rao A; Nayak VG; Ranganna G; Barve A Ther Adv Med Oncol; 2021; 13():17588359211045845. PubMed ID: 34819997 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Biosimilar SCT510 Compared with Bevacizumab for the First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study. Cheng Y; Pan Z; Wu L; Zhu B; Yu Y; Zang K; Zhuang W; Liu L; Gu K; Lian J; Chen R; Bian T; Lin D; Sun S; Li W; Hang X; Jiang O; Zhong F; Wang R; Luo H; Shi H; Wei Z; Zhao L; Chen S; Sun H; Li X; Sun D; Ren T; Lei K; He M; Li G; Liu H; Li R; Hu C; Kong L; Sun M; Xie L; Gai W; Chen W; Huang Z; Ren W; Su H Adv Ther; 2024 Nov; 41(11):4032-4048. PubMed ID: 39230871 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study. Qin S; Li J; Bai Y; Shu Y; Li W; Yin X; Cheng Y; Sun G; Deng Y; Zhong H; Li Y; Qian X; Zhang L; Zhang J; Chen K; Kang W; BioDrugs; 2021 Jul; 35(4):445-458. PubMed ID: 34014555 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study. Thatcher N; Goldschmidt JH; Thomas M; Schenker M; Pan Z; Paz-Ares Rodriguez L; Breder V; Ostoros G; Hanes V Clin Cancer Res; 2019 Apr; 25(7):2088-2095. PubMed ID: 30617139 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study. Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670 [TBL] [Abstract][Full Text] [Related]
16. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. Xu B; Zhang Q; Sun T; Li W; Teng Y; Hu X; Bondarenko I; Adamchuk H; Zhang L; Trukhin D; Wang S; Zheng H; Tong Z; Shparyk Y; Wang Q; BioDrugs; 2021 May; 35(3):337-350. PubMed ID: 33826080 [TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin Owen JS; Rackley RJ; Hummel MA; Roepcke S; Huang H; Liu M; Idris TA; Murugesan SMN; Marwah A; Loganathan S; Ranganna G; Barve A; Waller CF; Socinski MA Eur J Drug Metab Pharmacokinet; 2023 Nov; 48(6):675-689. PubMed ID: 37792130 [TBL] [Abstract][Full Text] [Related]
18. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers. Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267 [TBL] [Abstract][Full Text] [Related]
19. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers. Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067 [TBL] [Abstract][Full Text] [Related]
20. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers. Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]